“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

GSK (NYSE:GSK) reported its RSV vaccine Arexvy elicited a robust immune response in recipients aged 18 to 49 years who were ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

Earlier this year, GSK said it would invest £200 million (around $260 million) in upgrades to its manufacturing network in ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...

GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...

New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial Virus (RSV), generated protection against the virus over three full seasons ...

GSK’s RSV vaccine is the only RSV vaccine with ... to help recommending bodies determine future revaccination schedules AREXVY is the world’s first RSV vaccine and was approved based on ...